New concept about analyzing data of one hundreds h...
LIU Shanxi, JIANG Ling, HE Yueqin, et al.
Abatracta Objective To discuss pathology of hemophilia and its treaunent effect and feasibility of non-blood product remedy.Methods Through materials of 100 hemophilia in clinical, inspection the laboratory and result of the non-blood product medicine treatment, carried on analyzing and researching.Results Male was 97, female was 3.Medium age was 13.45(0.8~56)years old.The heredity history was 28, the heredity or the gene mutation unclear was 70, no heredity was 2.Three big illness complications were the low calcium blood sickness(73%), the hemophilia arthritis(68%)and the anemia(60%).Hemophilia classification: Single factor lacking sickness 76, double factor lacking sickness 18.three factors lacking sickness 6.Blood coagulation factor activeness reduced 72.73%(22/33)year by year, the relatively stability was 21.21%(7/33), raise slightly was 6.06%(2/33), changes of Fす:C was negatively related to growth of patient age and inventory of inputting factor Ⅷ(P＜ 0.05).The joint puncture has the hemorrhage only 7.5%(3/40), no blooding was 92.5%(37/40), joint capsule biopsy histological diagnosed pigmented villonodular synovitis.Treats for 6 months hy Xueyou Mixture, FVIII: C rises from(3.32±2.21)% to(16.38±2.71)%, FIX: C rises from(4.92+1.81)% to(11.62±5.23)%,(P＜ 0.01).Success ratio of treating hemorrhage was 100% by Zhixue Mixture, and completed 215 joints puncture 40 examples, the large area debridement, renew medicine and so on.By the antibacterial sterilization and injected the anti- inflammation io joint, 40 examples hemophilic arthritis alleviated rate 95% in short-term, for a long time is 85%.Conclusion Integration traditional Chinese and Western medicine therapy of the non-blood product can enhance blood coagulation factor activeness of hemophilia, hemostasis and have remarkable effect on the hemophilic arthritis.We have created a new way and idea for treating hemophilia。(https://www.daowen.com)
Key words Hemophilia; Data; Analyze; Non-blood product remedy; Treatment; Feasibility
血友病(hemophilia)是一组遗传性凝血因子缺乏性出血性疾病。到目前为止,该病仍缺乏根治性治疗。基因治疗因表达水平低微,维持时间短,腺病毒载体的强烈免疫反应及生殖链传递等问题而处于研究的低谷阶段。出血时,目前国内外除应用血液制品替代治疗外,别无更有效的方法。凝血因子不但价格昂贵,而且止血作用仅能维持24 h;反复应用,常易产生凝血因子抗体,灭活自身及输入的凝血因子,不但影响止血效果,而且使患者自身的凝血因子活性不断下降,形成恶性循环。并且常易合并乙型、丙型肝炎及艾滋病,成为世界性社会关注的问题。由于血友病的发病率低,因此也给研究和认识带来很大困难。陕西医大血液病研究院通过1年半,100例临床观察,发现了很多新问题和新认识,总结如下。